Dr. Qiu started Nexcelom from her basement in 2003, with the goal of automating manual cell counting and cell-based assays using image cytometry technologies. Over the past eighteen years, her team has developed chip-based, automated, bench-top cell counters for oncology, immunology, cell therapy during discovery, process development and manufacturing. In order to accurately count primary cells and measure viability of samples with heterogeneous compositions and debris, such as PBMCs, splenocytes, tumor digests, her team has expanded the viability stain beyond trypan blue to include dual-nuclear stains AO/PI for automated cell counters. Nexcelom Bioscience is now part of Perkin Elmer.
10:15 AM - 11:15 AM (PDT)
Thursday, June 16
During recent years, a few challenges and risks to patients have been reported emerging from viral…